Drug Trial Radar · NCT07474467
Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
31
Planned (sponsor's estimate)
Start
Aug 12, 2026
Primary completion
Feb 1, 2029
Study completion Aug 1, 2029
Sponsor
- Lead sponsor
- CellinCellsIndustry
- Sponsor type
- Industry
- First posted
- Mar 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial was to evaluate the safety and efficacy of a single administration of TRTP-101 in adults with atrophic scars.
Conditions
- Atrophic Scar
Interventions
TRTP-101Biological
Intradermal injection
PlaceboBiological
Intradermal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- [Phase 1] Number of Subjects with Dose Limiting ToxicityTime frame: within 4 weeks
- [Phase 2] Proportion of subjects achieving ≥ 1-grade improvement from baseline in ASRSTime frame: 12, 24 weeks after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Samsung Medical Center
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.